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As part of our ongoing investigation of filamentous fungi for anticancer leads, an active fungal 
extract was identified from the Mycosynthetix library (MSX 63935; related to Phoma sp.). The 
initial extract exhibited cytotoxic activity against the H460 (human non-small cell lung 
carcinoma) and SF268 (human astrocytoma) cell lines and was selected for further study. 
Bioactivity-directed fractionation yielded resorcylic acid lactones (RALs) 1 (a new natural 
product) and 3 (a new compound) and the known RALs zeaenol (2), (5E)-7-oxozeaenol (4), 
(5Z)-7-oxozeaenol (5), and LL-Z1640-1 (6). Reduction of (5E)-7-oxozeaenol (4) with sodium 
borohydride produced 3, which allowed assignment of the absolute configuration of 3. Other 
known resorcylic acid lactones (7–12) were purchased and assayed in parallel for cytotoxicity 
with isolated 1–6 to investigate structure–activity relationships in the series. Moreover, the 
isolated compounds (1–6) were examined for activity in a suite of biological assays, including 
antibacterial, mitochondria transmembrane potential, and NF-κB. In the latter assay, compounds 
1 and 5 displayed sub-micromolar activities that were on par with the positive control, and as 
such, these compounds may serve as a lead scaffold for future medicinal chemistry studies. 
 




In one component of our collaborative project to identify anticancer leads from diverse natural 
product study materials,(1, 2) extracts of filamentous fungi from the Mycosynthetix library, 
representing over 50 000 accessions, are being investigated systematically. Of the estimated 1.5 
million species of fungi in the world, only about 75 000 have been described in the literature,(3) 
and it is likely that an even smaller percentage have been pursued for bioactive secondary 
metabolites. Yet, many of the pharmaceutical breakthroughs of the 20th century originated in 
fungal cultures, including the well-known examples of antibiotics (i.e., penicillin),(4) 
immunosuppressants (e.g., cyclosporin A),(5) and cholesterol-lowering agents (e.g., 
compactin).(6) The recently approved natural product analogue fingolimod,(7) for the treatment 
of multiple sclerosis, and a clinical trial on psilocybin for terminally ill cancer patients(8) are but 
two examples that demonstrate contemporary interest in fungal secondary metabolites. 
Moreover, recent genomic data support the potential for fungi to biosynthesize a wealth of 
compounds.(9) In short, and as is often reported in this journal,(10) fungi from many different 
sources continue to be a valuable resource of bioactive secondary metabolites.(11) 
 
An extract of a filamentous fungus, MSX 63935, isolated from leaf litter collected in Nigeria, 
displayed promising cytotoxic activity against a human tumor panel.(12, 13) Previous research 
on this fungal isolate has examined a variety of biological targets, including assays for 
methicillin-resistant Staphylococcus aureus (MRSA), tuberculosis (TB), gene regulation, activity 
in the CNS, and various agricultural pests. However the only positive result was against MRSA, 
and no antibiotic compounds had been isolated.(14) Thus, these new cytotoxicity results 
spawned a bioactivity-directed fractionation study, and a series of resorcylic acid lactones 
(RALs; 1–6) were isolated and characterized, including a new natural product, 15-O-desmethyl-
(5Z)-7-oxozeaenol (1), and a new compound, 7-epi-zeaenol (3). In conjunction with structurally 
related analogues purchased from commercial sources, these compounds were evaluated against 
the human tumor panel, yielding preliminary structure–activity relationship data. The isolated 
compounds (1–6) were examined also for antibacterial activity, as well as activity in 
mitochondrial transmembrane potential and NF-κB inhibition assays. The NF-κB inhibition 





RESULTS AND DISCUSSION 
 
Through the ongoing exploration of extracts of filamentous fungi for cytotoxicity,(1) fungus 
MSX 63935 showed promising activity (i.e., >96% inhibition of H460 cell growth at 20 μg/mL). 
The solid-phase culture was scaled up to a 2.8 L Fernbach flask, and a 1:1 CHCl3/MeOH extract 
was generated, which was defatted with a 3:3:4 CH3CN/MeOH/hexanes partition. The resultant 
organic-soluble material was a white solid, which consisted almost exclusively of compounds1–
6 (see Figure S1 in the Supporting Information for an analytical HPLC of this solid). In fact, of 
all the anticancer leads examined from this library of filamentous fungi over the past three years, 
MSX 63935 was one of the most proficient producers of small molecules studied to date. This 
white solid was advanced directly to preparative scale RP-HPLC to isolate all six compounds in 
>95% purity, as measured by analytical HPLC. Compound 3 was a new compound, 1 was a new 
natural product, and 2, 4, 5, and 6 were known compounds. Of these, the production of 5 was 
quite high, in excess of 800 mg from a solid-phase culture grown in a 2.8 L Fernbach flask. 
 
The molecular formula for the major compound (5) was C19H22O7, as determined via HRESIMS. 
The NMR data, in conjunction with the HRMS data and UV maxima (from the PDA detector of 
the HPLC) at 234, 274, and 314 nm, indicated 5 to be the known compound (5Z)-7-oxozeaenol 
(also known as LL-Z1640-2),(15, 16) first described in 1978 by Ellestad and co-workers.(17)The 
[α]D of 5 was −83, compared to the literature value of −76, indicating the absolute configuration 
of 5 to be the same as LL-Z1640-2.(16) A reference standard was purchased, and the 1H NMR 
data were identical to the isolated compound (Table S1). The absolute configuration of 5 had 
been established by synthesis.(15, 16) 
 
The molecular formula for 1 was C18H20O7, as determined via HRESIMS. The 1H NMR spectra 
of 1 and 5 were very similar (see Tables 1 and S1). The major difference between the NMR data 
of 1 and 5 was the absence of the methoxy signals at δH/δC 3.80/55.5 in 1 that were present in5. 
A new phenol peak was observed at δH 10.39 in 1, further supporting the absence of a methoxy 
moiety in 1 relative to 5. Compound 1 has been described previously as an intermediate in the 
synthesis of 5;(16) however, it was ascribed the trivial name 15-O-desmethyl-(5Z)-7-oxozeaenol, 
since it had not been described from nature previously. The absolute configuration of 1 had been 




The HRESIMS data of compound 2 corresponded to a formula of C19H24O7, indicative of the 
addition of two protons relative to 5. The 1H NMR spectrum of 2 suggested the identity of 2 as 
zeaenol, and comparison of the NMR data to literature confirmed this assignment.(18)Moreover, 
the [α]D of 2 was −93, which matched literature data exactly.(18) The absolute configuration 
of 2 had been established previously by X-ray diffraction.(18) 
Compound 3 was isolated as a white powder, and the HRESIMS data also suggested a formula 
of C19H24O7 as with 2. The 1H NMR data of 3 were similar to 2; however, there were numerous 
signals that had shifted slightly compared to 2 (see Figures S4 and S5 for 1H and 13C NMR 
spectra, respectively, of 3). The COSY spectrum of 3 indicated the same carbon skeleton and 
oxygenation pattern as 2, suggesting that 2 and 3 were diastereomers. 
 
A recent report described a C-7 epimer (C-6′ in their numbering scheme) of aigialomycin B, 
which differs from 2 by the presence of an epoxide at C-11/C-12 (C-1′/C-2′ in their numbering 
scheme) instead of an alkene.(19) The same report described both C-7 epimers of 5,6-
dihydrozeaenol. Hence, given these literature precedents and the 2D-NMR data indicating 
that 3and 2 shared an identical skeleton and oxygenation pattern, it was hypothesized that 3 was 
the C-7 epimer of 2. The reduction of the C-7 ketone of (5E)-7-oxozeaenol (4; described below) 
was performed using sodium borohydride. The major product of the reduction of 4 had the 
identical retention time and UV spectrum to those of 3. Moreover, after isolation of the major 
reduction product by preparative HPLC, the 1H NMR data were identical to those of isolated 3, 
and thus, the configuration at C-7 for 3 was established as R. That 3 was the major product of the 
sodium borohydride reduction of 4 was somewhat surprising, as sodium borohydride is known to 
give mixtures of 1,4- and 1,2-reductions of α,β-unsaturated ketones; only a trace amount 
of 2 was detected by HPLC in the sodium borohydride reduction of 4. Regardless, these data 
supported the assignment of 3 as 7-epi-zeaenol. 
 
Compound 4 was isolated as a white powder. HRESIMS data indicated a formula identical to 5of 
C19H22O7. NMR data established 4 as the known compound (5E)-7-oxozeaenol.(18) To the best 
of our knowledge, the NMR data for 4 have not been reported previously, and thus they are 
summarized in Table S1. The [α]D value does not appear to have been reported either 
(seeExperimental Section). Moreover, since the acetonide of 4 has been reported, it was 
synthesized, and the 1H NMR data were in excellent agreement with literature data.(18) 
 
Compound 6 was isolated as a white powder. The HRESIMS data indicated a formula identical 
to 2 and 3 of C19H24O7. The NMR data for 6 matched that of LL-Z1640-1.(18) The [α]D of 6 was 
measured as −78, which compared favorably with the literature value of −81.(18) There appears 
to be some confusion in the literature about the absolute configuration of 6, which was 
determined initially by X-ray diffraction.(17) Sugawara et al.(18) later reported position C-8 as 
having an R configuration, whereas the X-ray studies(17) indicated C-8 as S; the latter 
assignment seems to be consistent on the basis of biosynthetic comparisons to the other isolated 
compounds. 
 
Compounds 1–6, along with other known RALs hypothemycin (7), zearalenone (8), α-zearalenol 
(9), β-zearalenol (10), α-zearalanol (11), and β-zearalanol (12) were assayed against the three 
cancer cell lines MCF-7, H460, and SF268. The IC50 results for 1–12 are summarized in Table2. 
From these, it was clear that the enone (i.e., compounds 1, 4, 5, and 7), but not exclusively acis-
enone (i.e., note 4), was required for cytotoxic activity. A recent review highlights some of the 
biology of the resorcylic acid lactones,(20) and they are known to inhibit with nanomolar 
potency the ATPase activity of two critical classes of proteins: the HSP90 chaperone(21, 22) and 
a subset of 16 kinases possessing a crucial cysteine residue in their ATPase binding 
pocket.(23)HSP90 client proteins include several oncogenic proteins, such as Src kinase, and 
HSP90 inhibition results in the dissociation and degradation of these proteins. The activity of the 





Compounds 1–6 were examined for activity in a series of three other assays. With respect to NF-
κB inhibitory activity, compound 5 (Table 3) was the most potent, being approximately a half-
order of magnitude less potent than the positive control (rocaglamide). Previously, 5 was 
reported as a potent inhibitor of TAK1, which is a member of the mitogen-activated kinase 
kinase kinase (MEKK) family that participates in proinflammatory cellular signaling pathways 
by activating NF-κB.(24) As with the cytotoxicity data, the enone moiety seemed to enhance 
potency, and in this case, the cis relationship (i.e., compounds 1 and 5) was more potent than 
the trans relationship (i.e., compound 4). In an assay for mitochondrial transmembrane potential 
(MTP), all compounds displayed IC50 values greater than 10 μM. Since the positive control for 
this assay, staurosporine, had an IC50 value in the single digit nanomolar range, 1–6 were 
considered inactive. Finally, compounds 1–6 were examined and found inactive 
againstEscherichia coli, Staphylococcus aureus, Mycobacterium smegmatis, and Bacillus 
subtilis; MIC values were all >500 μg/mL. 
 
 
In summary, a series of six structurally related resorcylic acid lactones (1–6) were isolated from 
MSX 63935. Data in both the cytotoxicity assays and the NF-κB assay suggest that 
compound 5was the most promising. Fortuitously, this fungus was a prolific producer of 5, 
generating over 800 mg per solid-phase culture in a 2.8 L Fernbach flask, using standard 
techniques prior to any growth optimization studies. As such, studies are ongoing to probe the 
structure–activity relationships further by using 5 as starting materials for medicinal chemistry 




General Experimental Procedures 
 
Optical rotations, UV spectra, and IR spectra were obtained on a Rudolph Research Autopol III 
polarimeter, a Varian Cary 100 Bio UV–vis spectrophotometer, and a Perkin-Elmer Spectrum 
One with Universal ATR attachment, respectively. NMR experiments were conducted in either 
DMSO-d6 or CDCl3 with TMS as reference. NMR instrumentation was a Bruker Ultrashield Plus 
with Avance III console, Topspin software version 2.1, and a QNP style Cryoprobe (operating at 
700.13 MHz for 1H, 176.05 MHz for 13C). A JEOL ECA-500 (operating at 500 MHz for 1H, 125 
MHz for 13C) was also used for some experiments. HRESIMS was performed on a Waters 
SYNAPT MS system. HPLC was carried out on Varian Prostar HPLC systems equipped with 
Prostar 210 pumps and a Prostar 335 photodiode array detector (PDA), with data collected and 
analyzed using Galaxie Chromatography Workstation software (version 1.9.3.2). For preparative 
HPLC, a Gemini-NX C18 (5 μm; 250 × 21.2 mm) column was used at a 21.2 mL/min flow rate, 
while for analytical HPLC, a Gemini-NX C18 (5 μm; 250 × 4.6 mm) column was used with a 1 
mL/min flow rate (both from Phenomenex, Inc.). Reference standards of (5Z)-7-oxozeaenol (5) 
and zeaenol (2) were obtained from EMD Chemicals. Zearalenone (8), α-zearalenol (9), β-
zearalenol (10), α-zearalanol (11), and β-zearalanol (12) were obtained from Sigma-Aldrich. 
Hypothemycin (7) was obtained from Enzo Life Sciences. All other reagents and solvents were 
obtained from Fisher Scientific and were used without further purification. 
 
Producing Organism and Fermentation 
 
Mycosynthetix fungal strain 63935 was isolated in 1992 by Dr. Barry Katz of MYCOsearch 
from leaf litter collected at the Agricultural Farms, University of Nigeria, Ede. DNA analyses 
were performed by MIDI Laboratories, Inc. (Newark, DE), and the D2 variable region of the 
large subunit (LSU) rRNA was sequenced and compared to their database; the closest match 
could determine only that this fungus was related to Phoma sp.; these data were deposited in 
Genbank (accession no. JF767207). The culture was stored on a malt extract slant and was 
transferred periodically. A fresh culture was grown on a similar slant, and a piece was transferred 
to a medium containing 2% soy peptone, 2% dextrose, and 1% yeast extract (YESD media). 
Following incubation (7 d) at 22 °C with agitation, the culture was used to inoculate 50 mL of a 
rice medium, prepared using rice to which was added a vitamin solution and twice the volume of 
rice with H2O, in a 250 mL Erlenmeyer flask. This was incubated at 22 °C until the culture 
showed good growth (approximately 14 d). The scale-up culture was grown in a 2.8 L Fernbach 
flask containing 150 g of rice and 300 mL of H2O and was inoculated using a seed culture grown 
in YESD medium. This was incubated at 22 °C for 14 d. 
Extraction and Isolation 
 
To the large-scale solid fermentation was added 500 mL of 1:1 MeOH/CHCl3. The mixture was 
shaken for 16 h, then filtered, and the solvent was evaporated (3.7 g of waxy, white solid). The 
extract was then partitioned between CH3CN/MeOH/hexanes (150/150/200 mL), the 
CH3CN/MeOH solubles were separated, and the solvent was evaporated (1.7 g of white powder, 
Figure S1, Supporting Information). As such, it was dissolved in 5.5 mL of DMSO and purified 
via seven separate injections by preparative HPLC using a gradient that initiated with 35:65 and 
increased linearly to 45:55 CH3CN/H2O over 40 min. Compound 1 eluted at ∼7.6 min (5.2 
mg),2 at ∼9 min (90.7 mg), 3 at ∼11.8 min (5.6 mg), and 4 at ∼14 min (73.1 mg), 
and 5 and 6eluted together from 16 to 20 min. The mixture of 5 and 6 was subjected to two 
further rounds of shave-and-recycle preparative HPLC under the same conditions to yield >95% 




white solid; [α]23D −59 (c 0.07, MeOH); UV (MeOH) λmax (log ε) 232 (4.35), 271 (3.89), 313 
(3.62) nm; IR (diamond) νmax 3348, 3146, 2951, 1690, 1646, 1602, 1467, 1350, 1312, 1259, 
1216, 1167, 1021, 965 cm–1; 1H NMR (DMSO-d6, 700 MHz) and 13C NMR (DMSO-d6, 175 
MHz), see Table 1; HRESIMS m/z 371.1100 [M + Na]+ and 347.1122 [M – H]− (calcd for 




white solid; [α]23D −91.9 (c 1.00, MeOH); 1H and 13C NMR data were in good agreement with 
the literature;(18) HRESIMS m/z 387.1413 [M + Na]+ and 363.1442 [M – H]− (calcd for 




white solid; [α]23D −90.4 (c 0.25, MeOH); UV (MeOH) λmax (log ε) 235 (4.30), 270 (3.94), 312 
(3.64) nm; IR (diamond) νmax 3376, 2965, 2930, 2899, 1636, 1602, 1571, 1353, 1312, 1248, 
1212, 1157, 1041, 971 cm–1; 1H NMR (DMSO-d6, 700 MHz) and 13C NMR (DMSO-d6, 175 
MHz), see Table 1; HRESIMS m/z 387.1410 [M + Na]+ and 363.1446 [M – H]− (calcd for 




white solid; [α]23D −27.0 (c 0.33, MeOH); 1H and 13C NMR (DMSO-d6, 500 MHz) data for 4, 
see Table 1; HRESIMS m/z 385.1257 [M + Na]+ and 361.1281 [M – H]− (calcd for C19H22O7Na, 




white solid; [α]23D −83.3 (c 0.34, MeOH); 1H and 13C NMR data were in good agreement with 
the literature;(15, 16) HRESIMS m/z 385.1252 [M + Na]+ and 361.1278 [M – H]− (calcd for 
C19H22O7Na, 385.1263; C19H21O7, 361.1287). 
LL-Z1640-1 (6): 
 
white solid; [α]23D −78.3 (c 0.33, MeOH); 1H and 13C NMR data were in good agreement with 
the literature;(18) HRESIMS m/z 387.1410 [M + Na]+ and 363.1424 [M – H]− (calcd for 
C19H24O7Na, 387.1420; C19H23O7, 363.1443). 
 
Acetonide of (5E)-7-Oxozeaenol (4a) 
 
To 1.54 mg of 4 were added 100 μL of 2,2-dimethoxypropane and 100 μL of acetone. A trace 
amount of pyridinium p-toluenesulfonate was added, and the solution was stirred for 2 h at 40 
°C. H2O (200 μL) was added to the solution, which was then injected directly onto 
semipreparative HPLC (ODS-A, 250 × 10 mm i.d., 5 μm; YMC). The elution proceeded at 4 
mL/min via a gradient that initiated with 50:50 and increased linearly over 20 min to 100:0 
CH3CN/H2O. The acetonide eluted from 14.7 to 15.3 min and was collected to yield 1.47 mg of 
4a (86% yield). The 1H NMR data of 4a were in excellent agreement with literature.(18) 
 
Reduction of 4 
 
(5E)-7-Oxozeaenol (4; 4.6 mg) was weighed into a 2 mL reaction vial, and 0.25 mL of both 2-
propanol and THF were added. The compound dissolved after brief stirring. NaBH4 (10.6 mg) 
was added with continued stirring. After 30 min, the solution had turned cloudy, and by 
analytical HPLC the presence of 4 was not discernible. H2O (0.5 mL) was added to this reaction 
product to dissolve all solids, and this solution was purified in a single step via preparative 
HPLC using the aforementioned conditions. The major peak was collected between 10 and 13 




The cytotoxicity measurements against the MCF-7(25) human breast carcinoma (Barbara A. 
Karmanos Cancer Center), NCI-H460(26) human large cell lung carcinoma (HTB-177, 
American Type Culture Collection (ATCC)), and SF-268(27) human astrocytoma (NCI 
Developmental Therapeutics Program) cell lines were performed as described 
previously.(13) Moreover, a second cytotoxicity assay was performed on only the isolated 
compounds using the HT-29(28)human colorectal adenocarcinoma (HTB-38, ATCC) and the 
MDA-MB-435(29) human melanoma (HTB-129, ATCC) cell lines. All cells were propagated in 
RPMI 1640 medium supplemented with fetal bovine serum (10%), penicillin (100 units/mL), and 
streptomycin (100 μg/mL). Cells were plated at either 2500 (HT-29) or 5000 (MCF-7, MDA-
MB-435) cells per well in 96-well microtiter plates and incubated for 16 h in a humidified, 5% 
CO2 atmosphere at 37 °C. Test substance was then added at the following final concentrations: 
25, 5, 1, 0.2, and 0.04 μg/mL. After a 72 h incubation, an MTS (3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt) assay was performed 
using a commercially available kit according to the manufacturer’s instructions (CellTiter 96 




Antibiotic activity was examined using an agar plate diffusion assay. Overnight cultures 
ofEscherichia coli, Staphylococcus aureus, Mycobacterium smegmatis, and Bacillus 
subtilis were used to inoculate molten LB media or Middlebrook 7H9 media (Difco) with 1% 
glycerol, containing 1.5% agar and kept at 50 °C; these were then used to prepare assay plates. 
Samples (dissolved in 10 μL of MeOH) were applied to the surface of the assay dish, and 
positive controls were treated in a similar manner (penicillin G, novobiocin, and streptomycin; 
all from Sigma). The bioassay plates were incubated overnight at 37 °C. Biological activity of 
the standards could be detected to 1 μg/mL (except that penicillin G was active against E. coli at 
100 μg/mL only), whereas the test compounds showed no activity at 500 μg/mL and were thus 
deemed inactive. 
 
NF-κB p65 Assay 
 
An ELISA-based NF-κB inhibitory assay was performed as described previously.(30) Briefly, 
HeLa cells (ATCC CCL-2) were treated with various concentrations of test compounds, positive 
control, or solvent control, and their nuclei extracted using the NE-PER kit (Pierce 
Biotechnology). The specific binding ability of activated p65 subunits of NF-κB in the nucleus 
was detected according to the manufacturer’s protocol (EZ-Detect Transcription Factor Assay 
System ELISA kit, Pierce). Rocaglamide (Enzo Life Sciences International, Inc.) was used as a 
positive control (IC50 value of 0.075 μM). 
 
Mitochondria Transmembrane Potential (ΔΨ) Assay 
 
The mitochondrial transmembrane potential assay kit (Cayman Chemical Company) was adapted 
to detect the ΔΨ using a procedure published previously.(31) ΔΨ is used to represent 
mitochondrial membrane transition events. Briefly, HT-29 cells were treated with various 
concentrations of the test compounds or positive control. Then, cells were incubated with the 
lipophilic cationic dye 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzymidazolylcarbocyanide (JC-
1; Cayman Chemical Company). After incubation, cells were rinsed with a wash buffer to 
remove unbound staining reagent. Samples were analyzed by a FLUOstar Optima fluorescence 
plate reader (BMG Labtech, Inc.) using an excitation wavelength of 485 nm and emission 
wavelength of 530 nm for JC-1 monomers from apoptotic cells and an excitation wavelength of 
560 nm and emission wavelength of 595 nm for JC-1-aggregates from healthy cells. 
Measurements were performed in triplicate and are representative of at least two independent 
experiments. For this assay, staurosporine (Cayman Chemical Company, Ann Arbor, MI) was 




Figure S1. Analytical HPLC of MeOH-CH3CN Partition. 35-40% MeCN in H2O over 20 




Figure S2. 1H NMR of 15-O-Desmethyl-5Z-7-oxozeaenol (1) in DMSO-d6 
 
 








































































Table S1. NMR Data for Known Compounds 4 and 5 (500 MHz, chemical shifts in δ, coupling 
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